Literature DB >> 11698200

Chemokine-based therapies for MS: how do we get there from here?

P Kivisäkk1, C Trebst, D J Eckstein, A P Kerza-Kwiatecki, R M Ransohoff.   

Abstract

The workshop on Multiple Sclerosis and Chemokines: Prospects for Therapeutic and Prophylactic Intervention was held in Chevy Chase, MD, USA, from 9-10 July 2001.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11698200     DOI： 10.1016/s1471-4906(01)02056-7

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  6 in total

1.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

2.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

3.  Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.

Authors:  Elizabeth R Comini-Frota; Antonio L Teixeira; Janaína P A Angelo; Marcus V Andrade; Doralina G Brum; Damacio R Kaimen-Maciel; Norma T Foss; Eduardo A Donadi
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 4.  Analysis of leukocyte extravasation across the blood-brain barrier: conceptual and technical aspects.

Authors:  Melissa K Callahan; Richard M Ransohoff
Journal:  Curr Allergy Asthma Rep       Date:  2004-01       Impact factor: 4.919

5.  N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats.

Authors:  Romesh Stanislaus; Anne G Gilg; Avtar K Singh; Inderjit Singh
Journal:  J Autoimmune Dis       Date:  2005-05-03

6.  Immune mechanisms in neurological disorders: protective or destructive?

Authors:  K Minton
Journal:  Trends Immunol       Date:  2001-12       Impact factor: 16.687
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.